JAMPRO
30.4.2021 15:34:12 CEST | Business Wire | Press release
Global outsourcing powerhouse, ibex , is increasing the diversity of jobs within Jamaica’s global digital services industry through an expansion of its current workforce of two thousand employees. The company provides customer support in sectors that include retail, finance, healthcare, and telecommunications, and it now offers a broad spectrum of business services from its Jamaican service centres.
With a client list heavily concentrated in the US, Europe, and Asia, ibex identified Jamaica as the perfect place for rapid expansion due to the island’s location and high-quality talent.
“ibex has experienced incredible growth in Jamaica - in the last three years we’ve grown 397%,” Country Director Jaime Vergara revealed. “We have gone from ranking as the 17th outsourcing company on the island for number of employees to number one, and ibex has been recognized for not only our growth, but for our performance, by organisations like Frost & Sullivan, a leading industry analyst group, and as Nexus Nearshore BPO of the Year in 2019 by Nearshore Americas.”
The high-calibre staff ibex has attracted has cleared the way for it to bring more business to Jamaica’s outsourcing industry and it now offers Knowledge Process Outsourcing (KPO) services from the island’s service centres. KPO is the outsourcing of information-related business activities such as accounting outsourcing, human resources (HR) outsourcing, digital marketing and management consultancy. Legal, medical and other healthcare analyses are additional examples of KPO.
As the world further relies on BPO and KPO during the COVID-19 pandemic, it is predicted that more business services will be digitised during and after the crisis. This and other factors will increase the demand for outsourcing, creating the environment for ibex to safely execute its growth plans both in Jamaica, and globally.
“We plan on prolonging our unprecedented growth and we hope to reach 10,000 employees in Jamaica over the next few years,” Vergara disclosed.
With the specialised skills needed for KPO, Vergara said Jamaica was the perfect location for ibex to offer these services. “Jamaica offers a talented and educated labour pool which is what has made us attractive to our clients, particularly in the financial services sector,” he said. “Through programs like the GSSP (Global Services Sector Project), the employees we hire are on a career path and are looking for companies to join where they can be successful. They are eager to work with their customers in their specialised area.”
Vergara also expressed appreciation for private and public sector partnerships including entities such as the Office of the Prime Minister, the Jamaica Special Economic Zone Authority (JSEZA) and the Jamaica Promotions Corporation (JAMPRO) among others.
JAMPRO, for example, has supported ibex as an investment facilitation partner, beginning with the launch of the first service centre in Portmore. The company now has five service centres across Jamaica.
ibex believes that its advancement into KPO has led to increased customer confidence, displaying the company’s adaptation to the needs of today’s clients. The company looks forward to more expansion in Jamaica.
ABOUT JAMPRO
The Jamaica Promotions Corporation (JAMPRO)’s mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce.
For more information on JAMPRO, please visit https://dobusinessjamaica.com/ .
Follow us on:
Twitter
Facebook
Instagram
LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20210430005093/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom